Home' The Source : First Quarter 2015 Contents BRIEF SUMMARY OF PRESCRIBING INFORMATION FOR
GRANIX (tbo-filgrastim) Injection, for subcutaneous use
SEE PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION
1 INDICATIONS AND USAGE
GRANIX is indicated to reduce the duration of severe neutropenia in patients
with non-myeloid malignancies receiving myelosuppressive anti-cancer
drugs associated with a clinically significant incidence of febrile neutropenia.
5 WARNINGS AND PRECAUTIONS
5.1 Splenic Rupture
Splenic rupture, including fatal cases, can occur following administration of
human granulocyte colony-stimulating factors. In patients who report upper
abdominal or shoulder pain after receiving GRANIX, discontinue GRANIX
and evaluate for an enlarged spleen or splenic rupture.
5.2 Acute Respiratory Distress Syndrome (ARDS)
Acute respiratory distress syndrome (ARDS) can occur in patients receiving
human granulocyte colony-stimulating factors. Evaluate patients who develop
fever and lung infiltrates or respiratory distress after receiving GRANIX, for
ARDS. Discontinue GRANIX in patients with ARDS.
5.3 Allergic Reactions
Serious allergic reactions including anaphylaxis can occur in patients receiv-
ing human granulocyte colony-stimulating factors. Reactions can occur on
initial exposure. The administration of antihistamines' steroids' bronchodi-
lators' and/or epinephrine may reduce the severity of the reactions. Perma-
nently discontinue GRANIX in patients with serious allergic reactions. Do
not administer GRANIX to patients with a history of serious allergic reac-
tions to filgrastim or pegfilgrastim.
5.4 Use in Patients with Sickle Cell Disease
Severe and sometimes fatal sickle cell crises can occur in patients with sickle
cell disease receiving human granulocyte colony-stimulating factors. Con-
sider the potential risks and benefits prior to the administration of human
granulocyte colony-stimulating factors in patients with sickle cell disease.
Discontinue GRANIX in patients undergoing a sickle cell crisis.
5.5 Potential for Tumor Growth Stimulatory Effects on Malignant Cells
The granulocyte colony-stimulating factor (G-CSF) receptor through which
GRANIX acts has been found on tumor cell lines. The possibility that GRANIX
acts as a growth factor for any tumor type, including myeloid malignancies and
myelodysplasia, diseases for which GRANIX is not approved, cannot be excluded.
6 ADVERSE REACTIONS
The following potential serious adverse reactions are discussed in greater
detail in other sections of the labeling:
see Warnings and Precautions (5.1)]
see Warnings and Precautions (5.2)]
see Warnings and Precautions (5.3)]
see Warnings and Precautions (5.4)]
Warnings and Precautions (5.5)]
The most common treatment-emergent adverse reaction that occurred at an
incidence of at least 1% or greater in patients treated with GRANIX at the
recommended dose and was numerically two times more frequent than in the
placebo group was bone pain.
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions,
adverse reaction rates observed in the clinical trials of a drug cannot be
directly compared to rates in the clinical trials of another drug and may not
reflect the rates observed in clinical practice.
GRANIX clinical trials safety data are based upon the results of three ran-
domized clinical trials in patients receiving myeloablative chemotherapy for
breast cancer (N=348), lung cancer (N=240) and non-Hodgkin s lymphoma
(N=92). In the breast cancer study, 99% of patients were female, the median
age was 50 years, and 86% of patients were Caucasian. In the lung cancer
study, 80% of patients were male, the median age was 58 years, and 95%
of patients were Caucasian. In the non-Hodgkin s lymphoma study, 52% of
patients were male, the median age was 55 years, and 88% of patients were
Caucasian. In all three studies a placebo (Cycle 1 of the breast cancer study
only) or a non-US-approved filgrastim product were used as controls. Both
GRANIX and the non-US-approved filgrastim product were administered at
5 mcg/kg subcutaneously once daily beginning one day after chemotherapy
for at least five days and continued to a maximum of 14 days or until an ANC
of 10,000 x 106/L after nadir was reached.
Bone pain was the most frequent treatment-emergent adverse reaction that
occurred in at least 1% or greater in patients treated with GRANIX at the recom-
mended dose and was numerically two times more frequent than in the placebo
group. The overall incidence of bone pain in Cycle 1 of treatment was 3.4%
(3.4% GRANIX, 1.4% placebo, 7.5% non-US-approved filgrastim product).
In clinical studies, leukocytosis (WBC counts > 100,000 x 106/L) was observed
in less than 1% patients with non-myeloid malignancies receiving GRANIX.
No complications attributable to leukocytosis were reported in clinical studies.
As with all therapeutic proteins, there is a potential for immunogenicity. The
incidence of antibody development in patients receiving GRANIX has not
been adequately determined.
7 DRUG INTERACTIONS
No formal drug interaction studies between GRANIX and other drugs have
Drugs which may potentiate the release of neutrophils' such as lithium'
should be used with caution.
Increased hematopoietic activity of the bone marrow in response to growth
factor therapy has been associated with transient positive bone imaging
changes. This should be considered when interpreting bone-imaging results.
8 USE IN SPECIFIC POPULATIONS
Pregnancy Category C
There are no adequate and well-controlled studies of GRANIX in pregnant
women. In an embryofetal developmental study, treatment of pregnant rab-
bits with tbo-filgrastim resulted in adverse embryofetal findings, including
increased spontaneous abortion and fetal malformations at a maternally toxic
dose. GRANIX should be used during pregnancy only if the potential benefit
justifies the potential risk to the fetus.
In the embryofetal developmental study, pregnant rabbits were administered
subcutaneous doses of tbo-filgrastim during the period of organogenesis
at 1, 10 and 100 mcg/kg/day. Increased abortions were evident in rabbits
treated with tbo-filgrastim at 100 mcg/kg/day. This dose was maternally toxic
as demonstrated by reduced body weight. Other embryofetal findings at this
dose level consisted of post-implantation loss' decrease in mean live litter
size and fetal weight, and fetal malformations such as malformed hindlimbs
and cleft palate. The dose of 100 mcg/kg/day corresponds to a systemic
exposure (AUC0-24) of approximately 50-90 times the exposures observed in
patients treated with the clinical tbo-filgrastim dose of 5 mcg/kg/day.
8.3 Nursing Mothers
It is not known whether tbo-filgrastim is secreted in human milk. Because
many drugs are excreted in human milk, caution should be exercised when
GRANIX is administered to a nursing woman. Other recombinant G-CSF
products are poorly secreted in breast milk and G-CSF is not orally absorbed
8.4 Pediatric Use
The safety and effectiveness of GRANIX in pediatric patients have not been
8.5 Geriatric Use
Among 677 cancer patients enrolled in clinical trials of GRANIX, a total of 111
patients were 65 years of age and older. No overall differences in safety or effec-
tiveness were observed between patients age 65 and older and younger patients.
8.6 Renal Impairment
The safety and efficacy of GRANIX have not been studied in patients with
moderate or severe renal impairment. No dose adjustment is recommended
for patients with mild renal impairment.
8.7 Hepatic Impairment
The safety and efficacy of GRANIX have not been studied in patients with
No case of overdose has been reported.
©2013 Cephalon, Inc., a wholly owned subsidiary of Teva Pharmaceutical
Industries Ltd. All rights reserved.
GRANIX is a trademark of Teva Pharmaceutical Industries Ltd.
Sicor Biotech UAB
Teva Pharmaceuticals USA, Inc.
North Wales, PA 19454
U.S. License No. 1803
Product of Israel
GRX-40188 January 2014
This brief summary is based on TBO-003 GRANIX full Prescribing Information.
Links Archive Fourth Quarter 2014 Second Quarter 2015 Navigation Previous Page Next Page